Nadolol

beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM

Key facts

Nadolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1979. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 3 molecular targets, including ADRB2, ADRB1 and ADRB3. Recorded indications include Angina pectoris and Hypertensive disorder.

• Approval status: ofp (first approved 1979 by the FDA).
• Drug class: beta-Adrenergic Blocker.
• Mechanism of action: Adrenergic beta-Antagonists.
• Molecular targets: ADRB2, ADRB1 and ADRB3 (3 listed in DrugCentral).
• Indications: Angina pectoris and Hypertensive disorder.
• ATC code: C07AA12 (Beta blocking agents, non-selective).
• Molecular formula: C17H27NO4; molecular weight 309.41 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Angina pectoris
• Hypertensive disorder

Off-label uses (7)

• Essential tremor
• Migraine Prevention
• Mitral valve prolapse
• Myocardial Reinfarction Prevention
• Prevention of Bleeding Esophageal Varices
• Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia
• Thyrotoxicosis

Contraindications (33)

• Acute nephropathy
• Acute pancreatitis
• Anaphylaxis
• Anuria
• Bronchospasm
• Cardiogenic shock
• Complete atrioventricular block
• Decompensated cardiac failure
• Depressive disorder
• Diabetes mellitus
• Disease of liver
• Gout
• Hepatic coma
• Hypercalcemia
• Hypercholesterolemia
• Hyperparathyroidism
• Hyperuricemia
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Kidney disease
• Myasthenia gravis
• Neonatal hyperbilirubinemia
• Oliguria
• Partial atrioventricular block
• Pregnancy, function
• Pulmonary emphysema
• Raynaud's phenomenon
• Right ventricular failure
• Severe chronic obstructive pulmonary disease
• + 3 more

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta-Antagonists
• Established pharmacologic class: beta-Adrenergic Blocker

Molecular targets (3)

Target	Gene	Action	Activity
Beta-2 adrenergic receptor	ADRB2	antagonist	Ki 8.60
Beta-1 adrenergic receptor	ADRB1	antagonist	Ki 6.90
Beta-3 adrenergic receptor	ADRB3	antagonist	Ki 6.30

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1979-12-10	FDA	—	KING PHARMS

ATC classification

ATC code	Therapeutic hierarchy
C07AA12	CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, non-selective
C07BA12	CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND THIAZIDES › Beta blocking agents, non-selective, and thiazides

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Macular degeneration	1687.5
Chronic sinusitis	624.9
Vaginal flatulence	536.5
Paraesthesia oral	516.3
Female genital tract fistula	511.4
Radiculopathy	475.8
Proctitis	475.0
Vaginal discharge	469.8
Procedural pain	435.5
Oral candidiasis	333.7
Rectal haemorrhage	291.1
Frequent bowel movements	283.3

Chemical structure

• Molecular formula: C₁₇H₂₇NO₄
• Molecular weight: 309.41 g/mol
• CAS number: 42200-33-9
• InChIKey: VWPOSFSPZNDTMJ-UHFFFAOYSA-N
• PubChem CID: 39147

CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nadolol used for?

DrugCentral lists the following indications for Nadolol: Angina pectoris and Hypertensive disorder.

How does Nadolol work?

Nadolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB2 (antagonist), ADRB1 (antagonist) and ADRB3 (antagonist).

When was Nadolol first approved?

Nadolol was first approved by the FDA in 1979.

What drug class does Nadolol belong to?

Nadolol is in the beta-Adrenergic Blocker class.

What is the chemical formula of Nadolol?

Nadolol has the molecular formula C17H27NO4 and a molecular weight of 309.41 g/mol.

Sources

• DrugCentral drug card 1865 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL521606 — compound record and bioactivity
• PubChem CID 39147 — chemical identifiers
• DrugBank DB01203 — drug record
• FDA UNII FEN504330V — substance identity
• DailyMed: FDA labels for Nadolol — current prescribing information (label search)
• UniProt P07550 (ADRB2) — target protein
• UniProt P08588 (ADRB1) — target protein
• UniProt P13945 (ADRB3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.